Lilly's Taltz (ixekizumab) Receives Health Canada Approval for Non-Radiographic Axial Spondyloarthritis
Shots:
- The approval is based on P-lll COAST-X study assessing Taltz (80mg- q4w) vs PBO for the treatment of adult patients with nr-axSpA with objective signs of inflammation for 52wks.
- Result: 1EPs of ASAS40 @16wks. (35% vs 19%); ASAS40 response @52wks. (30% vs 13%)- met its 2EPs- showing efficacy in reducing disease activity and sacroiliac joint inflammation- improving patient function & QoL- the safety profile is consistent with the previous study
- Taltz is a mAb that selectively binds with IL-17A cytokine and inhibits its interaction with the IL-17 receptor
Ref: Newswire Canada | Image: Everyday Health
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com